Melanoma, arising predominantly from clonally multiplying pigment cells, may rapidly become metastatic and spread to secondary organs (the lungs, liver, brain, pleura). In their study, K.Värv, R. Rumvolt, L. Järvekülg, M. Drews and R. Ehin of the Competence Centre for Cancer Research, Tallinn University of Technology aimed to develop a novel NK cell cultivation and activation strategy based on peripheral blood mononuclear cell (PBMC) fraction, using good manufacturing practice (GMP) compliant components. The cytotoxic potential of the produced in vitro propagated and activated NK cells against different human melanoma cell lines was assessed.